MA25035A1 - Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant - Google Patents

Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant

Info

Publication number
MA25035A1
MA25035A1 MA25862A MA25862A MA25035A1 MA 25035 A1 MA25035 A1 MA 25035A1 MA 25862 A MA25862 A MA 25862A MA 25862 A MA25862 A MA 25862A MA 25035 A1 MA25035 A1 MA 25035A1
Authority
MA
Morocco
Prior art keywords
preparation
compositions containing
azabicyclo
new
hexane derivatives
Prior art date
Application number
MA25862A
Other languages
English (en)
Inventor
Joseph Banks Bernard
James Crook Robert
Lunn Graham
John Pettman Alan
Paul Gibson Stephen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828485.4A external-priority patent/GB9828485D0/en
Priority claimed from GBGB9912425.7A external-priority patent/GB9912425D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA25035A1 publication Critical patent/MA25035A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (1) DANS LAQUELLE LES GROUPES R1, R2, R3, R4, R5, R6, R7, R8, R9, R1O ET X REPRÉSENTENT DIVERS RADICAUX ET AR REPRÉSENTE UN GROUPE ZRYLE. ELLE CONCERNE ÉGALEMENT UN PROCÉDÉ POUR LEUR PRÉPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE DIVERSES MALADIES À MÉDIATION PAR DES RECEPTEURS D'OPIACÉS.
MA25862A 1998-12-23 1999-12-08 Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant MA25035A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828485.4A GB9828485D0 (en) 1998-12-23 1998-12-23 Compounds useful in therapy
GBGB9912425.7A GB9912425D0 (en) 1999-05-27 1999-05-27 Compounds useful in therapy
US09/467,871 US6313312B1 (en) 1998-12-23 1999-12-20 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy

Publications (1)

Publication Number Publication Date
MA25035A1 true MA25035A1 (fr) 2000-07-01

Family

ID=27269601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25862A MA25035A1 (fr) 1998-12-23 1999-12-08 Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant

Country Status (33)

Country Link
US (3) US6313312B1 (fr)
EP (1) EP1140828B1 (fr)
JP (1) JP3553886B2 (fr)
CN (1) CN1192021C (fr)
AP (1) AP1852A (fr)
AT (1) ATE335725T1 (fr)
AU (1) AU761574B2 (fr)
BG (1) BG65402B1 (fr)
BR (1) BR9916584A (fr)
CA (1) CA2356300C (fr)
CY (1) CY1106445T1 (fr)
CZ (1) CZ20012299A3 (fr)
DE (1) DE69932738T2 (fr)
DK (1) DK1140828T3 (fr)
DZ (1) DZ2962A1 (fr)
EA (1) EA004672B1 (fr)
ES (1) ES2274646T3 (fr)
HK (1) HK1041698B (fr)
HR (1) HRP20010477B1 (fr)
HU (1) HUP0104816A3 (fr)
ID (1) ID28981A (fr)
IL (1) IL142697A0 (fr)
IS (1) IS2467B (fr)
MA (1) MA25035A1 (fr)
NO (1) NO321658B1 (fr)
NZ (1) NZ511234A (fr)
OA (1) OA11727A (fr)
PL (1) PL348453A1 (fr)
SI (1) SI1140828T1 (fr)
SK (1) SK8772001A3 (fr)
TW (1) TWI244481B (fr)
UY (1) UY25873A1 (fr)
WO (1) WO2000039089A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
IL161157A0 (en) * 2001-10-22 2004-08-31 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
US7265147B2 (en) * 2002-07-31 2007-09-04 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
CN1688544A (zh) * 2002-08-23 2005-10-26 兰贝克赛实验室有限公司 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (fr) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
CA2521685A1 (fr) * 2003-04-09 2004-10-21 Pharmacia & Upjohn Company Llc Derives de [3.1.0] bicyclohexylphenyl-oxazolidinone antimicrobiens et leurs analogues
EP1626957A1 (fr) * 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Derives azabicyclo utiles comme antagonistes du recepteur muscarinique
CA2522323C (fr) * 2003-04-14 2009-09-15 Pfizer Products Inc. Derives de 3-azabicyclo[3.2.1]octane comme ligands de recepteurs opioides
RU2006112576A (ru) * 2003-10-16 2006-08-27 Пфайзер Продактс Инк. (Us) Получение производных 3-азабицикло [3.1.0] гексана
WO2006024955A1 (fr) * 2004-09-01 2006-03-09 Pfizer Products Inc. Antagonistes des recepteurs d'amine histamine-3 azabicycliques
US20060235037A1 (en) * 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
EP1888525A1 (fr) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited Derives d'azabicyclo [3.1.0]hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
AU2006269231A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
GB0716632D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Compounds
US7691878B2 (en) * 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029257A1 (fr) * 2007-08-27 2009-03-05 Theravance, Inc. Composes d'alkyl-8-azabicyclo[3.2.1.]octane disubstitutes utilises en tant qu'antagonistes du recepteur opioide mu
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
WO2009029252A1 (fr) * 2007-08-27 2009-03-05 Theravance, Inc. Composés d'amidoalkyle-8-azabicyclo[3.2.1]octane en tant qu'antagonistes du récepteur opioïde mu
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
EP2776437B1 (fr) * 2011-11-07 2018-09-26 Sunovion Pharmaceuticals Inc. Modulateurs de récepteurs des opioïdes et leurs procédés d'utilisation
WO2015076310A1 (fr) 2013-11-20 2015-05-28 株式会社 三和化学研究所 Nouveau dérivé 3-azabicyclo[3.1.0]hexane et son utilisation à des fins médicales
SG11201606351VA (en) 2014-02-03 2016-09-29 Quadriga Biosciences Inc Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
US9394236B2 (en) 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted γ-amino acids and analogs as chemotherapeutic agents
CN104177284B (zh) * 2014-08-01 2016-08-24 常州大学 合成3-氮杂二环[3,1,0]己基-1-甲醛的方法
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2016186184A1 (fr) * 2015-05-20 2016-11-24 株式会社 三和化学研究所 Cristal de sel de nouveau dérivé de 3-azabicyclo[3.1.0]hexane et son utilisation pharmaceutique
EP3331851A1 (fr) 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Acides bêta-aminés substitués en bêta et analogues à utiliser en tant qu'agents de chimiothérapie et leurs utilisations
WO2017121692A1 (fr) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Sulfamides substitués et leur utilisation
WO2018159716A1 (fr) 2017-03-02 2018-09-07 株式会社 三和化学研究所 Agent thérapeutique pour troubles liés à la consommation d'alcool
CA3061787A1 (fr) * 2017-05-15 2018-11-22 Cognition Therapeutics, Inc. Compositions pour le traitement de maladies neurodegeneratives
CN107501272B (zh) * 2017-09-05 2020-03-31 中国药科大学 咪唑并异吲哚类ido1抑制剂、其制备方法及应用
EP3749667A1 (fr) 2018-02-05 2020-12-16 Alkermes, Inc. Composés pour le traitement de la douleur
CN112939844B (zh) * 2019-12-10 2023-02-03 华东师范大学 一种多取代四氢咔唑及其衍生物及其合成方法和应用
CN110938036A (zh) * 2019-12-24 2020-03-31 中国药科大学 一种4-碘-1h-咪唑的制备方法
EP4146645B1 (fr) 2020-05-07 2025-06-25 ONO Pharmaceutical Co., Ltd. Dérivés de 3-azabicyclo(3.1.0)hexane ayant une activité inhibitrice de kdm5 et leur utilisation
CN112300002A (zh) * 2020-10-26 2021-02-02 安徽工业大学 一种5-硝基丹皮酚及5-硝基丹皮酚腙的制备方法
CN114057627B (zh) * 2022-01-18 2022-04-01 南京桦冠生物技术有限公司 一种丙型肝炎及新冠药物中间体及其盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872300A (en) * 1956-10-26 1961-07-05 Wellcome Found Improvements in and relating to new derivatives of azabicyclohexane and the manufacture thereof
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
GB948730A (en) * 1959-04-08 1964-02-05 Wellcome Found Substituted cyclopropanes and related compounds
EP0287339B1 (fr) 1987-04-16 1994-08-17 Eli Lilly And Company Pipéridines comme antagonistes d'opioids
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
CY1106445T1 (el) 2011-10-12
SK8772001A3 (en) 2002-03-05
CN1192021C (zh) 2005-03-09
TWI244481B (en) 2005-12-01
IS5922A (is) 2001-04-20
UY25873A1 (es) 2001-08-27
JP2002533440A (ja) 2002-10-08
AP1852A (en) 2008-05-29
EA200100417A1 (ru) 2001-12-24
IL142697A0 (en) 2002-03-10
EA004672B1 (ru) 2004-06-24
HRP20010477B1 (en) 2007-03-31
BG65402B1 (bg) 2008-06-30
PL348453A1 (en) 2002-05-20
CN1331679A (zh) 2002-01-16
DK1140828T3 (da) 2006-12-11
DE69932738D1 (de) 2006-09-21
AU761574B2 (en) 2003-06-05
ATE335725T1 (de) 2006-09-15
SI1140828T1 (sl) 2007-02-28
OA11727A (en) 2004-11-08
CA2356300A1 (fr) 2000-07-06
HK1041698B (zh) 2005-09-02
US20020072616A1 (en) 2002-06-13
HRP20010477A2 (en) 2002-08-31
HUP0104816A2 (hu) 2002-04-29
BR9916584A (pt) 2001-10-16
HUP0104816A3 (en) 2002-06-28
US6313312B1 (en) 2001-11-06
CA2356300C (fr) 2008-12-30
BG105711A (en) 2002-02-28
JP3553886B2 (ja) 2004-08-11
US7049444B2 (en) 2006-05-23
AU1069800A (en) 2000-07-31
NO321658B1 (no) 2006-06-19
EP1140828B1 (fr) 2006-08-09
EP1140828A1 (fr) 2001-10-10
ES2274646T3 (es) 2007-05-16
AP2001002185A0 (en) 2001-06-30
NO20013148L (no) 2001-08-23
US20030013875A1 (en) 2003-01-16
NZ511234A (en) 2003-09-26
NO20013148D0 (no) 2001-06-22
WO2000039089A1 (fr) 2000-07-06
ID28981A (id) 2001-07-19
HK1041698A1 (en) 2002-07-19
DE69932738T2 (de) 2007-08-09
DZ2962A1 (fr) 2004-03-15
CZ20012299A3 (cs) 2001-12-12
IS2467B (is) 2008-12-15

Similar Documents

Publication Publication Date Title
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA24729A1 (fr) Macrolides nouveaux.
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26729A1 (fr) Modulateurs nouveaux des recepteurs de glucocorticoides, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26720A1 (fr) Composes nouveaux inhibiteurs de reabsorption de monoamines, procede pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
DE69723869D1 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
MA26717A1 (fr) Macrolides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
TNSN98185A1 (fr) Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98151A1 (fr) Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole.
TNSN99111A1 (fr) Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.